UNASSIGNED: Primary @entity3039 is an @entity792 of unknown cause affecting both @entity1 and adults. The low peripheral blood platelet count is caused by premature @entity1423 by self-reacting antibodies in addition to an @entity1423 . The disease is heterogeneous in its pathophysiology, clinical features and responses to treatment. To date, most of the treatments used have been immune-modulating drugs and these contribute to increased morbidity and mortality in @entity1 . A new class of drugs, the thrombopoietin receptor agonists, has been developed for use in @entity3039 . These have gone through randomised controlled trials in large numbers of @entity1 with @entity3039 . These drugs have high efficacy and are well tolerated. In addition, around 30% of @entity1 receiving these drugs are able to stop them and maintain a safe or normal platelet count. Older treatments such as splenectomy are being used less than before, largely because of the introduction of the thrombopoietin receptor agonists. Currently there are trials underway evaluating novel therapies for @entity3039 that will become available over the next few years once the trials are complete.

Current Management of Primary XXXX .

@entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity3039 :: ('MESH:D016553', 'Disease') :: ['ITP', 'immune thrombocytopenia'] @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune disorder'] @entity1423 :: ('MESH:D001791', 'Disease') :: ['platelet destruction', 'impairment of platelet production']
@entity3039 :: (MESH:D016553,Disease) :: ['Immune Thrombocytopenia']
